Lobbying | Health Policy | Regulation

The FDA’s September 2026 public hearing makes a larger truth visible: when a treatment depends on hours of supervision, specialized practitioners and an unusually controlled setting, approval of the compound cannot settle the policy. Advocates must help design a care system they can defend in public.

By Frank Farnel | Responsible Public Affairs | September 21, 2026

Executive Summary

• On September 14, 2026, the U.S. Food and Drug Administration held a public hearing on the potential future therapeutic use of psychedelic drug products in supervised and supportive settings. Written comments remain open until October 5. The phrasing matters: the policy question is already wider than whether a compound works.
• Psychedelic medicine creates a joined-up lobbying problem. Evidence standards, therapist or facilitator roles, clinical sites, controlled-substance rules, reimbursement, advertising and post-treatment monitoring can be governed by different institutions. Winning one decision may still leave the treatment unavailable, unaffordable or unsafe.
• The 2024 review of Lykos Therapeutics’ MDMA application showed the cost of allowing public enthusiasm to run ahead of the regulatory record. An FDA advisory committee voted 9–2 that the available data did not show effectiveness and 10–1 that benefits did not outweigh risks under the proposed safeguards. FDA’s subsequent complete response letter requested another trial and identified evidence and safety-data problems.
• Australia demonstrates a different path. It permits specially authorized psychiatrists to prescribe MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression, yet the products remain unapproved goods, access is tightly conditioned, public advertising is prohibited and treatment is not subsidized through the Pharmaceutical Benefits Scheme.
• Responsible advocacy should work through five connected questions: Claim, Context, Competence, Coverage and Control. A persuasive argument for access that ignores any one of them is not a complete policy proposition.

The Hearing Behind the Headline

“Psychedelic medicine” can sound like a single policy file. It is not. It is a stack of decisions distributed across medicines regulators, controlled-substance authorities, professional bodies, ethics committees, health insurers, state governments, hospital systems and legislators. Each institution sees a different object. One sees a drug. Another sees a clinical service. A third sees a high-risk professional activity. A fourth sees a reimbursement code, a workforce constraint or a diversion risk.

That fragmentation is now moving to the center of the American debate. On September 14, the FDA convened a four-hour Part 15 public hearing, in collaboration with federal partners, to seek views on the “potential future therapeutic use” of drug products containing psychedelic substances in supervised and supportive settings. The agency set October 5 as the deadline for written comments.¹ In July, it had already issued final guidance on clinical investigations of psychedelic drugs, formalizing recommendations first proposed in 2023.²

The careful language is more revealing than a dramatic announcement would have been. FDA did not announce a class-wide endorsement, a new approval pathway or a conclusion that these products are safe and effective. A hearing solicits evidence and perspective; guidance explains the agency’s current thinking for development programs. Neither substitutes for review of a specific application.

Still, the hearing matters. It opens a legitimate policy window in which patients, clinicians, researchers, developers, professional associations, insurers and public-interest organizations can help regulators understand what a workable model would require. For lobbying practitioners, it is also a test. The easy argument is that severe psychiatric conditions create an unmet need and promising research deserves attention. That argument may be true, but it is incomplete. The difficult task is to show how a treatment model can preserve scientific rigor, protect patients in unusually vulnerable states, create an accountable workforce and become practically accessible without turning regulatory uncertainty into promotional opportunity.

This is not a conventional campaign for approval. It is advocacy over the architecture surrounding a possible approval.

From Product Lobbying to System Lobbying

Traditional pharmaceutical advocacy often follows a familiar chain: establish disease burden, demonstrate clinical value, secure authorization, obtain favorable coverage and support adoption. That chain is already more complex than its simplified description. Psychedelic-assisted treatment adds a structural complication: the intervention may be inseparable, in practice and sometimes in the evidence base, from preparation, a prolonged supervised dosing session, psychological support, a controlled environment and follow-up.

The resulting policy object is neither simply a pill nor simply psychotherapy. It is a compound embedded in a protocol and delivered by a team. Regulation can therefore fail in two opposite directions. It can treat the drug as if the surrounding service were incidental, leaving critical safeguards underspecified. Or it can build a service so demanding, expensive and scarce that formal access exists mostly on paper.

The lobbying problem is one of institutional fit. A sponsor may be able to generate data on its product but not license therapists. A professional association may define clinical competence but not decide federal scheduling. An insurer may reimburse a drug while declining to cover the hours of professional time needed to administer it. A state may authorize a service model that sits outside federal drug approval. Each partial decision can be internally rational and collectively dysfunctional.

For experienced public-affairs leaders, the implication is uncomfortable but useful: the objective cannot be reduced to “get the regulator to yes.” It must be to help public institutions construct a model in which a defensible yes can operate—and a justified no remains possible.

The Five-C Mandate

A credible policy position can be tested through five connected questions. They are not a checklist for manufacturing consensus. They are a discipline for exposing what an advocacy campaign has and has not proved.

Policy question	What decision-makers need to know	Evidence that carries weight	Common advocacy failure
Claim	What precisely is claimed for which product, indication and patient population?	Controlled trials, transparent adverse-event reporting, durability data, subgroup limits and reproducible protocols	Converting hope, unmet need or class-wide promise into a product-specific conclusion
Context	Which elements of setting and psychological support are necessary to reproduce the observed benefit and manage risk?	Protocol components, site requirements, monitoring and discharge criteria, emergency procedures and comparative designs	Treating the setting as branding when it may be part of the intervention
Competence	Who may prescribe, administer, supervise and provide psychological support—and who is accountable?	Independent training standards, licensing, supervision, scope-of-practice rules, complaints mechanisms and workforce analysis	Promoting a new treatment faster than a qualified and governable workforce can be built
Coverage	Who pays for the product, preparation, supervised session, facility and follow-up?	Total care-pathway cost, staffing assumptions, payment codes, capacity modeling and equity analysis	Celebrating legal access while ignoring economic access
Control	How are manufacturing, storage, advertising, diversion, safety reporting and postmarket learning governed?	Quality standards, controlled-drug compliance, surveillance, independent reporting and enforceable promotion rules	Assuming restrictions end at approval or that self-regulation will resolve conflicts of interest

Claim: define the proposition narrowly enough to test it

Advocacy often begins with a broad sentence: psychedelics could transform mental-health care. Public authority cannot act responsibly on that sentence. It needs a defined product, dose, regimen, indication, population, comparator and outcome. It also needs to know how long any benefit persists and whether the study design permits that benefit to be attributed to the product.

This distinction is particularly important where a drug’s noticeable psychoactive effects make blinding difficult. A participant may infer whether they received the active product; expectations can then influence reporting. The problem does not prove that an observed benefit is unreal. It does mean that trial design and interpretation require unusual care. A lobbying document that dismisses the issue is weaker than one that explains how it can be measured and mitigated.

Context: the room may be part of the intervention

FDA’s hearing notice explicitly refers to supervised and supportive settings. That is not decorative language. The physical site, preparation, staffing, monitoring, duration of observation and follow-up may affect both benefit and risk. If psychological support contributes materially to outcomes, regulators must understand what support means, whether it can be standardized and how to separate the effects of the drug from the effects of the accompanying intervention.

The policy debate therefore cannot be captured by dose and label alone. It must address whether treatment can occur only in certified facilities, what equipment and emergency capacity those facilities need, what constitutes readiness for discharge, and what happens if a patient experiences distress after leaving.

Competence: enthusiasm is not a professional qualification

A care model that places patients in states of altered consciousness concentrates power in the hands of those supervising them. Training is therefore not just a scaling challenge; it is a safeguarding issue. The relevant questions extend beyond how many hours a course should contain. Who accredits the course? Must trainers be independent from the product sponsor? Which profession retains clinical accountability? How are boundary violations reported? Can a patient identify a clear route for complaint and redress?

The professional coalition matters here. An advocacy strategy constructed only by drug developers will be institutionally incomplete. Psychiatrists, psychologists, nurses, pharmacists, ethics specialists, patient representatives and facility operators may hold different parts of the practical answer. Their interests will not always align, which is precisely why policymakers need to hear them separately as well as collectively.

Coverage: permission is not access

A supervised session can occupy a treatment room and multiple professionals for many hours. Preparation and integration add further time. Even if the medicine itself were inexpensive, the service might not be. A viable policy must therefore confront reimbursement, workforce supply and opportunity cost.

Coverage arguments should state what is included. Does the proposed payment cover screening, preparation, the drug, the full dosing session, two supervisors if required, medical monitoring, follow-up and adverse-event management? If an insurer covers only the product, the formal benefit may remain beyond the reach of many patients. If reimbursement is generous but training capacity is scarce, queues and geographic inequity may follow.

Control: approval begins a governance cycle

Controlled-substance handling, product quality, promotional boundaries and postmarket safety are not administrative footnotes. They shape legitimacy. This field also carries an unusual risk of the public conversation outrunning authorized claims. Research findings, personal testimony, investment narratives and wellness marketing can blur together long before a regulator approves a product.

Responsible lobbying protects the distinction. It does not imply that participation in a hearing is regulatory endorsement. It does not advertise access that the law does not permit. And it supports surveillance capable of detecting harms that preapproval studies may be too small or too selective to reveal.

Case One: The FDA’s 2026 Window Is About a Model, Not a Shortcut

The sequence of events in 2026 deserves careful reading. In July, FDA issued its final guidance for clinical investigations of psychedelic drugs. The agency described growing interest in therapeutic potential while emphasizing that these trials present distinctive design challenges.² Two months later, it convened a public hearing about possible therapeutic use in supervised and supportive settings.¹

The sequence creates an opportunity for influence, but not the one a promotional campaign might prefer. The guidance does not lower the evidentiary bar. The hearing does not prejudge an application. Rather, the two processes invite the field to improve the quality of the questions and the operational detail of possible answers.

Submissions that merely repeat the scale of unmet need will add little. Regulators already understand that many patients do not benefit sufficiently from current treatments. More useful contributions will specify how to handle functional unblinding, how psychological support should be characterized, what data demonstrate durability, what monitoring a treatment site needs and how adverse events can be captured without depending on the same actors whose conduct is being assessed.

This is where lobbying can contribute legitimate expertise. Developers can explain manufacturing and protocols. Clinicians can test whether safeguards are operationally realistic. Patient organizations can identify burdens and risks invisible in a sponsor’s model. Payers can expose reimbursement assumptions. State regulators can describe conflicts among professional, facility and controlled-substance rules.

The most credible coalition will not present a frictionless consensus if one does not exist. It will map disagreements, disclose interests and offer regulators choices with consequences. In a field where public excitement is already high, precision is a political asset.

Case Two: Lykos and the Limits of Momentum

The Lykos case is a warning against confusing cultural momentum, patient need and positive trial publications with regulatory sufficiency.

Two Phase 3 studies published in Nature Medicine reported favorable outcomes for MDMA-assisted therapy in PTSD.³⁴ Those publications formed part of a larger dossier, not its conclusion. In June 2024, FDA’s Psychopharmacologic Drugs Advisory Committee considered the company’s application for midomafetamine capsules. The committee voted 2–9 on whether available data showed effectiveness and 1–10 on whether benefits outweighed risks under the proposed risk-management strategy.⁵

The committee’s concerns reached into every part of the care model: functional unblinding and expectation bias; durability; the contribution of psychological intervention; boundary violations; incomplete safety characterization; possible diversion; monitoring; discharge criteria; and the independence and medical competence of therapists. This was not a rejection of the possibility that MDMA might one day help some patients. It was a judgment about whether this application, evidence package and proposed delivery safeguards met the standard at that time.

FDA’s August 2024 complete response letter was still more specific. It said the application had not established substantial evidence of effectiveness, identified serious concerns about the reliability of safety data, and described a new randomized study with blinded long-term follow-up as the most efficient path to resolve clinical issues. The agency also asked for better characterization of durability, bias, abuse-related adverse events, discharge readiness and the contribution of psychotherapy.⁶

ICER’s independent assessment reached a related but carefully bounded conclusion: publicly available evidence was insufficient to assess the balance of benefits and harms for the Lykos intervention, in part because of functional unblinding and concerns about trial design and conduct.⁷ Insufficient evidence is not evidence of no benefit. That distinction is essential—and politically difficult.

The lobbying lesson is not that advocacy failed because the company lacked access, storytelling or committed supporters. It is that advocacy could not repair the underlying regulatory record. Indeed, the louder the surrounding expectation, the more damaging any attempt to minimize unresolved evidence or safeguarding questions becomes.

For public-affairs practitioners, this case establishes a useful boundary. Patient testimony can illuminate urgency and lived experience. It cannot replace controlled evidence. Expert advocacy can explain why a trial design is reasonable. It cannot make avoidable uncertainty disappear. Political support may encourage an agency to prioritize a field. It should not be used to pressure scientific reviewers into treating an incomplete dossier as complete.

Case Three: Australia Shows What “Access” Actually Contains

Australia is often described in a single sentence: in 2023 it became the first country to permit authorized psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. The sentence is accurate but easily misunderstood.

The Therapeutic Goods Administration did not register these products as approved medicines. They remain unapproved therapeutic goods accessed through the Authorised Prescriber scheme. The psychiatrist must hold specialist registration, secure approval from a registered Human Research Ethics Committee and obtain TGA authorization for the product and indication. Patients cannot take the products home. Other indications remain in the prohibited-substance category outside research.⁸

The care setting is also regulated. TGA’s updated guidance expects a medically supervised facility equipped for clinical care, monitoring, emergency response and secure controlled-drug handling, located within 15 minutes of an accredited emergency department. The prescriber remains responsible for the protocol, site, supply path and reporting. Authorizations are generally time-limited, and patient numbers must be reported every six months.

Nor does legal access equal broad affordability. The products are not eligible for Australia’s Pharmaceutical Benefits Scheme because they are unapproved; treatment costs must be met by the patient or a third party. Public advertising by practitioners or facilities is prohibited. The rule is important for the politics of access: the system allows treatment under defined conditions while limiting the creation of consumer demand through promotion.⁸

The model has continued to evolve. In May 2026, after a targeted consultation, roundtable and stakeholder discussions, TGA published recommendations clarifying psychiatrist competence, therapy-team composition, prescriber oversight and treatment-site standards. It explicitly framed the task as balancing appropriate access with strong patient-safety safeguards.⁹

Australia therefore offers neither a simple success story nor a simple cautionary tale. It offers something more useful: a demonstration that rescheduling is only the first visible layer of policy. A working regime must allocate responsibility across the prescriber, ethics committee, regulator, treatment site, product supplier and state or territorial authorities. It must also decide what happens when lawful access is not publicly funded.

For lobbyists, the comparative lesson is clear. Importing one attractive feature from another jurisdiction—the headline permission—without importing its safeguards, institutional responsibilities and financing conditions produces a misleading policy comparison.

What the Debate Is—and Is Not—About

It is possible to hold three positions at once.

First, several psychedelic compounds merit serious clinical research. The burden of PTSD, treatment-resistant depression and other mental-health conditions makes the search for better treatments a legitimate public priority. Positive findings should not be dismissed because a substance also has a history outside medicine.

Second, promise at the level of a scientific field is not the same as sufficient evidence for a specific product and regimen. Regulators approve defined applications, not cultural movements. Different compounds, formulations, indications, protocols and delivery settings require separate judgments.

Third, excessive or poorly coordinated regulation can itself create harm. If rules require scarce specialists, expensive sites and hours of unreimbursed supervision without a viable payment model, access may be confined to wealthy urban patients. If federal and state requirements conflict, capable providers may stay out. If promotional restrictions are vague, responsible actors may remain silent while less disciplined voices dominate public understanding.

A balanced lobbying strategy must be able to discuss all three without collapsing them into a slogan. The purpose of engagement is not maximum restriction or maximum speed. It is a regime whose evidence standards, safeguards and access model are mutually coherent.

What Lobbying Leaders Should Do Now

1. Submit an institutional answer, not a product brochure. Comments to the FDA hearing docket should explain which agency or profession would own each part of the delivery model. Unsupported adjectives—transformative, groundbreaking, urgent—carry less weight than a responsibility map.
2. Separate class advocacy from product advocacy. A case for continued research or a workable regulatory pathway is not evidence that a named product meets approval standards. Make the distinction explicit in public materials, testimony and coalition governance.
3. Put unfavorable evidence in the main document. Address blinding, durability, adverse-event collection, boundary risks, workforce scarcity and cost directly. Regulators will find these issues. Voluntary candor improves credibility and helps decision-makers distinguish analysis from promotion.
4. Build a coalition with visible independence. Patients, clinicians, sponsors, payers and facility operators should not be presented as interchangeable validators. Disclose funding and disagreements. Where training, data review or complaints mechanisms should be independent of a sponsor, say so.
5. Model the full episode of care. Estimate staff hours, rooms, screening, emergency readiness, controlled-drug handling, follow-up and likely payer treatment. A reimbursement proposal that prices only the drug is not an access strategy.
6. Design promotion rules before the market. Establish a clear line among scientific exchange, public education, patient recruitment and advertising. This is especially important when public awareness precedes authorization and clinics have incentives to signal availability.
7. Use comparative policy honestly. When citing Australia or a subnational service model, include its limits: product approval status, prescriber restrictions, site requirements, funding, advertising and reporting. A foreign headline without its operating conditions is advocacy by omission.
8. Plan for postmarket correction. If a product is eventually authorized, support registries, independent adverse-event channels, audit rights and periodic reassessment. A new model should be capable of learning—and of tightening or withdrawing permissions when evidence requires it.

Conclusion: Lobby the Care System You Are Prepared to Operate

The political attraction of psychedelic medicine is understandable. It combines urgent need, compelling personal accounts, serious scientific inquiry and the possibility of a different therapeutic model. Those same qualities create pressure to compress uncertainty into a simple contest between innovation and obstruction.

That would be a mistake. The central policy question is not whether institutions are “for” or “against” psychedelics. It is whether a specific intervention can be evaluated honestly, delivered by competent people, supervised in an appropriate setting, financed without exclusion and controlled throughout its life cycle.

The FDA’s 2026 hearing gives stakeholders a legitimate opportunity to shape that answer. The strongest lobbying will not ask public authorities to treat the surrounding architecture as someone else’s problem. It will bring the architecture into the case.

A medicine can pass through a regulatory gate. A model of care must survive the world beyond it.

Key Evidence

• September 14, 2026: FDA held a Part 15 hearing on potential future therapeutic use of psychedelic drug products in supervised and supportive settings; written comments close October 5.¹
• July 2026: FDA issued final guidance on clinical investigations of psychedelic drugs, finalizing its June 2023 draft.²
• 2–9 and 1–10: The June 2024 FDA advisory-committee votes on whether Lykos’ data showed effectiveness and whether benefits outweighed risks under the proposed safeguards.⁵
• New trial requested: FDA’s complete response letter described another randomized study with blinded long-term follow-up as the most efficient way to address the clinical issues.⁶
• Australia: Authorized access is limited to specialist psychiatrists for MDMA in PTSD and psilocybin in treatment-resistant depression; the products remain unapproved, cannot be taken home and are not PBS-listed.⁸

Glossary

Authorised Prescriber schemeAn Australian pathway allowing approved medical practitioners to prescribe specified unapproved therapeutic goods to defined classes of patients under conditions.Complete response letterAn FDA communication explaining that an application cannot be approved in its present form and identifying deficiencies that must be addressed. It is not a permanent class-wide prohibition.Functional unblindingA situation in which participants or investigators infer treatment assignment because the effects of the active intervention are recognizable, potentially influencing expectations or assessments.Part 15 hearingAn FDA public hearing used to obtain views and information under procedures in Title 21 of the Code of Federal Regulations.REMSA Risk Evaluation and Mitigation Strategy: an FDA-required safety program for certain medicines with serious risks.Unapproved therapeutic goodIn Australia, a product not included in the Australian Register of Therapeutic Goods and therefore not evaluated by TGA as an approved medicine, though access may be possible through specified pathways.

References and Further Reading

Official and regulatory sources

1. U.S. Food and Drug Administration, “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing,” September 14, 2026.
2. U.S. Food and Drug Administration, “Psychedelic Drugs: Considerations for Clinical Investigations,” final guidance, July 2026.
3. U.S. Food and Drug Administration, “June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee: Summary Minutes,” June 2024.
4. U.S. Food and Drug Administration, “Complete Response Letter: NDA 215455, Midomafetamine Capsules,” August 8, 2024.
5. Therapeutic Goods Administration, “Accessing MDMA and Psilocybine as a Psychiatrist,” published February 13, 2023; updated June 22, 2026.
6. Therapeutic Goods Administration, “Updates to Authorised Prescriber Scheme Requirements When Accessing MDMA and Psilocybine,” May 26, 2026.
7. Therapeutic Goods Administration, “Change to Classification of Psilocybin and MDMA to Enable Prescribing by Authorised Psychiatrists,” February 3, 2023.

Clinical and independent evidence assessments

8. Jennifer M. Mitchell et al., “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study,” Nature Medicine, Vol. 27, 2021, pp. 1025–1033.
9. Jennifer M. Mitchell et al., “MDMA-Assisted Therapy for Moderate to Severe PTSD: A Randomized, Placebo-Controlled Phase 3 Trial,” Nature Medicine, Vol. 29, 2023, pp. 2473–2480.
10. Institute for Clinical and Economic Review, “Post-Traumatic Stress Disorder: An Assessment of MDMA-Assisted Therapy,” final evidence report and meeting summary, June 27, 2024.
11. Jessica Colcott et al., “Side-Effects of MDMA-Assisted Psychotherapy: A Systematic Review and Meta-Analysis,” Neuropsychopharmacology, 2024.

Related Responsible Public Affairs analysis

12. Frank Farnel, “The Test Becomes the Argument: How Regulatory Sandboxes Are Changing Lobbying,” Responsible Public Affairs, August 2026.
13. Frank Farnel, “The Deal Needs a Political License: Lobbying in the Age of Investment Screening,” Responsible Public Affairs, September 7, 2026.
14. Frank Farnel, “The Tender Is the Policy: Lobbying Before the Public Buyer Writes the Rules,” Responsible Public Affairs, September 14, 2026.

Source and Methodology Note

Research was completed on September 21, 2026. The article prioritizes FDA and Australian TGA documents, including guidance, hearing materials, advisory-committee minutes and the publicly released complete response letter. Peer-reviewed trials are included to represent the positive clinical findings that preceded the U.S. regulatory review; the ICER assessment and FDA record are used to explain subsequent evidentiary and safety concerns.

The article does not evaluate individual treatment decisions and is not medical advice. It distinguishes three levels of evidence: published trial findings, regulatory judgments about a specific application, and the author’s policy analysis. The FDA’s 2026 hearing is a consultative process, not an approval or commitment to approve. Australia’s Authorised Prescriber pathway provides controlled access to unapproved goods; it should not be described as ordinary product registration. The Five-C Mandate is the author’s analytical framework.

Suggested Internal Links

• The Test Becomes the Argument: How Regulatory Sandboxes Are Changing Lobbying
• The Deal Needs a Political License: Lobbying in the Age of Investment Screening
• The Tender Is the Policy: Lobbying Before the Public Buyer Writes the Rules

Hashtags: #ResponsibleLobbying #HealthPolicy #PsychedelicMedicine